Current challenges and opportunities for liquid biopsies.Liquid biopsies serve as an indispensable clinical diagnostic tool when traditional biopsies are difficult to obtain or yield inadequate samples for genetic mon...Current challenges and opportunities for liquid biopsies.Liquid biopsies serve as an indispensable clinical diagnostic tool when traditional biopsies are difficult to obtain or yield inadequate samples for genetic monitoring.However,achieving optimal sensitivity and stability poses a significant challenge due to the difficulty of detecting low levels of plasmatic cell-free DNA(cfDNA).Recently,Dr.Carmen Martin-Alonso and colleagues[1]reported that priming agents,consisting of nanoparticles and DNA-binding monoclonal antibodies(mAbs),could significantly improve the sensitivity and robustness of liquid biopsies.The innovative use of priming agents promises improved liquid biopsies across various clinical applications by enhancing efficacy,accuracy,and depth of ex vivo sequencing and analysis.Importantly,it reduces the need to draw large blood volumes from patients or perform extensive plasma exchange to obtain sufficient cfDNA(Table 1).展开更多
基金supported by the Construction Project of Liaoning Provincial Key LaboratoryChina(2022JH13/10200026)+5 种基金Fund of the Affiliated Xiangshan Hospital of Wenzhou Medical UniversityWenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical UniversityWenzhouDepartment of Hepatobiliary SurgeryThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhou Institute University of Chinese Academy of Sciences。
文摘Current challenges and opportunities for liquid biopsies.Liquid biopsies serve as an indispensable clinical diagnostic tool when traditional biopsies are difficult to obtain or yield inadequate samples for genetic monitoring.However,achieving optimal sensitivity and stability poses a significant challenge due to the difficulty of detecting low levels of plasmatic cell-free DNA(cfDNA).Recently,Dr.Carmen Martin-Alonso and colleagues[1]reported that priming agents,consisting of nanoparticles and DNA-binding monoclonal antibodies(mAbs),could significantly improve the sensitivity and robustness of liquid biopsies.The innovative use of priming agents promises improved liquid biopsies across various clinical applications by enhancing efficacy,accuracy,and depth of ex vivo sequencing and analysis.Importantly,it reduces the need to draw large blood volumes from patients or perform extensive plasma exchange to obtain sufficient cfDNA(Table 1).
